Ipca Labs to Merge Krebs Biochemicals to Strengthen Fermentation API Business

According to the company, Krebs Biochemicals & Industries Ltd. will be the Transferor Company, while Ipca Laboratories Ltd. will be the Transferee Company. The scheme carries an appointed date of April 1, 2026, and will become effective after receipt of all statutory and regulatory approvals as specified in the scheme.

The disclosure states that the standalone audited total income of Ipca Laboratories for the financial year ended March 31, 2026, stood at Rs 7,431 crore, while Krebs Biochemicals reported audited total income of Rs 26 crore, primarily comprising conversion charges received from Ipca Laboratories. The company informed that the proposed amalgamation qualifies as a related party transaction, but it is being undertaken on an arm's length basis. Both companies are engaged in the manufacturing and marketing of pharmaceuticals.

Ipca Laboratories said the merger is expected to generate operational synergies, resulting in cost optimisation, while enabling consolidation of the businesses of both companies. The company stated that the amalgamation would also reduce administrative responsibilities, duplication of records and statutory, legal and regulatory compliances.

The company further explained that Krebs Biochemicals possesses manufacturing capabilities for fermentation-based active pharmaceutical ingredients (APIs), a capability currently not available with Ipca Laboratories. Following the merger, Ipca expects to strengthen its ability to research, develop and commercialise new fermentation-based APIs, thereby expanding its business.

The disclosure also highlighted that Krebs manufactures a fermentation-based API used as the therapeutic ingredient in Ipca Laboratories' largest-selling formulation, with only a limited number of manufacturers globally producing the ingredient. The merger is expected to secure an uninterrupted supply of this API. In addition, Krebs manufactures drug intermediates used by Ipca in the production of key active pharmaceutical ingredients, and the amalgamation is expected to ensure a continuous supply of these intermediates.

According to the company, Krebs Biochemicals has been continuously incurring losses and has been unable to invest adequately in research and development for new fermentation-based APIs. Ipca stated that the merger will enable the business to benefit from the financial strength, technical expertise and marketing capabilities of the combined entity.

As part of the scheme, no cash consideration will be paid. Instead, shareholders of Krebs Biochemicals, other than Ipca Laboratories, will receive seven fully paid-up equity shares of Re 1 each of Ipca Laboratories for every 200 fully paid-up equity shares of Rs 10 each held in Krebs Biochemicals on the record date to be determined under the scheme. The equity and preference shares of Krebs Biochemicals already held by Ipca Laboratories will stand cancelled and extinguished upon the scheme becoming effective, and no shares or consideration will be issued against those holdings.

According to the regulatory filing submitted by Ipca Laboratories, the proposed amalgamation will also result in a marginal change in the company's shareholding pattern. The promoter shareholding is expected to decrease from 44.72% to 44.66%, while public shareholding will increase from 55.28% to 55.34% following the issue of shares to eligible shareholders of Krebs Biochemicals under the approved exchange ratio.